Cell and Gene Therapy Access Model - PPMCO
Customize your policy alerts
Sign up for johns_hopkins_health_plans Policy CMS24.26 alerts
Get alerted when Policy CMS24.26 changes without checking for updates manually.
Monitor payer policy activity
Governs prior authorization, clinical criteria, authorized treatment centers, and coverage processes for CASGEVY and LYFGENIA under the Maryland Cell and Gene Therapy Access Model as applied by Johns Hopkins Health Plans (Priority Partners Managed Care Organization). Affects members with sickle cell disease seeking these gene therapies and providers/ATCs administering them.
University of Maryland Medical Center (UMMC) was added as an approved treatment center for CASGEVY effective 01/26/2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.